|
Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
This item is licensed under:Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
| Title: | Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma |
| Authors: | Sakakibara-Konishi, Jun Browse this author →KAKEN DB | | Sato, Mineyoshi Browse this author | | Sato, Michiko Takimoto Browse this author | | Kasahara, Kohei Browse this author | | Onozawa, Masahiro Browse this author | | Mizugaki, Hidenori Browse this author →KAKEN DB | | Kikuchi, Eiki Browse this author →KAKEN DB | | Asahina, Hajime Browse this author →KAKEN DB | | Shinagawa, Naofumi Browse this author →KAKEN DB | | Konno, Satoshi Browse this author →KAKEN DB |
| Keywords: | Malignant pleural mesothelioma | | Nivolumab | | Immune thrombocytopenia |
| Issue Date: | 2020 |
| Publisher: | Elsevier |
| Journal Title: | Respiratory Medicine Case Reports |
| Volume: | 31 |
| Start Page: | 101170 |
| Publisher DOI: | 10.1016/j.rmcr.2020.101170 |
| Abstract: | Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018. Immune related adverse event (irAE) is occurred in various organs and is suggestive to be related to better outcome of nivolumab. Frequency of hematological irAE is low and there are few reports about hematological irAE and association between irAE and outcome of nivolumab in patients with MPM. We present a case of recurrent MPM who responded to nivolumab treatment and experienced nivolumab-induced immune thrombocytopenia (ITP). Although high dose dexamethasone was administered and platelet count increased transiently, re-administration of dexamethasone was required to maintain normal count of platelet. The careful and intensive management of ITP treatment is necessary in cases who show no response or relapse to initial glucocorticoids treatment. This is the first report about nivolumab-induced ITP and association with response to nivolumab in MPM. |
| Rights: | https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/80442 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
